JonesResearch analyst Justin Walsh reiterates a Buy rating on Radiopharm (RADX) and announced a $30 price target on the U.S. shares. The firm remains “intrigued” by the potential of the company’s “diverse” radiopharmaceutical pipeline and believes the market is “dramatically undervaluing the opportunity.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RADX:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue